Fluad Tetra 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0043 
C.I.6.a - Change(s) to therapeutic indication(s) - 
09/11/2023 
07/12/2023 
SmPC, 
Please refer to Scientific Discussion Fluad Tetra 
Addition of a new therapeutic indication or 
modification of an approved one 
Labelling and 
EMEA/H/C/004993/II/0043. 
PL 
IA/0050 
B.I.a.1.f - Change in the manufacturer of AS or of a 
04/12/2023 
n/a 
starting material/reagent/intermediate for AS - 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
  
 
 
 
 
 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0048 
B.II.b.4.f - Change in the batch size (including batch 
23/11/2023 
n/a 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
IA/0049 
A.4 - Administrative change - Change in the name 
17/11/2023 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0047/G 
This was an application for a group of variations. 
17/11/2023 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10300
Periodic Safety Update EU Single assessment - 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202303 
influenza vaccine (surface antigen, inactivated, 
adjuvanted) 
II/0045 
B.I.a.5.a - Changes to the AS of a seasonal, 
06/07/2023 
24/07/2023 
SmPC, 
As a result of this variation, Section 2 of the SmPC 
prepandemic or pandemic vaccine against human 
Labelling and 
(qualitative and quantitative composition) has been 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
influenza - Replacement of the strain(s) in a 
seasonal, prepandemic or a pandemic vaccine 
against human influenza 
PL 
updated to reflect the changes in influenza strains included 
in the 2023/2024 formulation.  
The SmPC section 2 has been updated as follows:  
• 
A/Victoria/4897/2022 (H1N1)pdm09-like virus 
(A/Victoria/4897/2022 IVR-238) 
• 
A/Darwin/9/2021 (H3N2)-like virus 
(A/Darwin/6/2021 IVR-227) 
• 
B/Austria/1359417/2021 (B/Victoria Lineage)-like 
virus (B/Austria/1359417/2021 BVR-26) 
• 
B/Phuket/3073/2013 (B/Yamagata Lineage)-like 
virus (B/Phuket/3073/2013 BVR-1B) 
The Labelling, package leaflet and Annex A have been 
updated accordingly. 
N/0044 
Minor change in labelling or package leaflet not 
17/05/2023 
24/07/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0042/G 
This was an application for a group of variations. 
27/04/2023 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0040/G 
This was an application for a group of variations. 
28/03/2023 
n/a 
B.II.b.4.f - Change in the batch size (including batch 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
duplication of line) 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0041/G 
This was an application for a group of variations. 
10/03/2023 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
IB/0037/G 
This was an application for a group of variations. 
21/02/2023 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
IB/0039 
B.I.a.2.a - Changes in the manufacturing process of 
03/02/2023 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
II/0036 
B.I.c.1.b - Change in immediate packaging of the AS 
02/02/2023 
n/a 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Qualitative and/or quantitative composition for 
sterile and non-frozen biological/immunological ASs 
IB/0038/G 
This was an application for a group of variations. 
01/02/2023 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
Page 5/14 
 
 
 
 
 
 
 
 
 
(including replacement or addition) 
IB/0034 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
13/01/2023 
24/07/2023 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0035 
B.II.b.5.z - Change to in-process tests or limits 
07/12/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0033 
B.II.b.5.z - Change to in-process tests or limits 
14/11/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IA/0032 
B.II.d.1.a - Change in the specification parameters 
03/10/2022 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
PSUSA/10300
Periodic Safety Update EU Single assessment - 
29/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
influenza vaccine (surface antigen, inactivated, 
adjuvanted) 
II/0030 
B.I.a.5.a - Changes to the AS of a seasonal, 
23/06/2022 
22/07/2022 
SmPC, 
As a result of this variation, Section 2 of the SmPC 
prepandemic or pandemic vaccine against human 
Labelling and 
(qualitative and quantitative composition) has been 
influenza - Replacement of the strain(s) in a 
seasonal, prepandemic or a pandemic vaccine 
against human influenza 
PL 
updated to reflect the changes in Influenza strains included 
in the NH 2022/2023 formulation. 
The virus strains included in the vaccine for the season 
2022-2023 are:  
A/Victoria/2570/2019 (H1N1)pdm09-like virus 
(A/Victoria/2570/2019 IVR-215); 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0029 
A.7 - Administrative change - Deletion of 
23/03/2022 
n/a 
manufacturing sites 
IB/0027 
B.II.z - Quality change - Finished product - Other 
25/02/2022 
n/a 
variation 
II/0021 
B.II.b.1.c - Replacement or addition of a 
24/02/2022 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
IA/0028 
B.I.b.2.a - Change in test procedure for AS or 
04/02/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0026/G 
This was an application for a group of variations. 
22/12/2021 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
A/Darwin/9/2021 (H3N2)-like virus (A/Darwin/6/2021 IVR-
227); 
B/Austria/1359417/2021 (B/Victoria lineage)-like virus 
(B/Austria/1359417/2021 BVR-26); 
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus 
(B/Phuket/3073/2013 BVR-1B). 
Labelling, Package leaflet and Annex A are updated 
accordingly. 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0025 
B.I.b.2.e - Change in test procedure for AS or 
20/12/2021 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0024 
B.I.d.1.c - Stability of AS - Change in the re-test 
15/12/2021 
n/a 
period/storage period or storage conditions - Change 
to an approved stability protocol 
IB/0023 
B.II.b.2.a - Change to importer, batch release 
15/12/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0022 
B.I.a.2.a - Changes in the manufacturing process of 
06/12/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020/G 
This was an application for a group of variations. 
30/11/2021 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IA/0019/G 
This was an application for a group of variations. 
06/10/2021 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10300
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
influenza vaccine (surface antigen, inactivated, 
adjuvanted) 
II/0017 
B.I.a.5.a - Changes to the AS of a seasonal, 
08/07/2021 
23/07/2021 
SmPC, 
As a result of this variation, Section 2 of the SmPC 
prepandemic or pandemic vaccine against human 
Labelling and 
(qualitative and quantitative composition) has been 
influenza - Replacement of the strain(s) in a 
seasonal, prepandemic or a pandemic vaccine 
against human influenza 
PL 
updated to reflect the changes in Influenza strains included 
in the NH 2021/2022 formulation.  
The virus strains included in the vaccine for the season 
2021-2022 are:  
A/Victoria/2570/2019 (H1N1)pdm09-like virus 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0016 
B.II.b.2.c.1 - Change to importer, batch release 
19/04/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0015/G 
This was an application for a group of variations. 
14/04/2021 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
(A/Victoria/2570/2019 IVR-215) 
A/Cambodia/e0826360/2020 (H3N2)-like virus 
(A/Cambodia/e0826360/2020 IVR-224 
B/Washington/02/2019 (B/Victoria lineage)-like virus 
(B/Victoria/705/2018 BVR-11) 
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus 
(B/Phuket/3073/2013 BVR-1B) 
Labelling and Package leaflet are updated accordingly. 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0014 
B.II.f.1.e - Stability of FP - Change to an approved 
17/03/2021 
n/a 
stability protocol 
IB/0012 
B.II.g.5.c - Implementation of changes foreseen in 
08/03/2021 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
IA/0013 
A.7 - Administrative change - Deletion of 
01/03/2021 
23/07/2021 
Annex II and 
manufacturing sites 
PL 
IB/0010 
B.I.b.2.e - Change in test procedure for AS or 
08/02/2021 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0007/G 
This was an application for a group of variations. 
02/02/2021 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
IB/0011 
B.I.a.2.a - Changes in the manufacturing process of 
18/01/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0008 
C.I.11.b - Introduction of, or change(s) to, the 
14/01/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
IAIN/0009/G 
This was an application for a group of variations. 
20/11/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0006 
B.I.b.1.d - Change in the specification parameters 
05/11/2020 
n/a 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0005/G 
This was an application for a group of variations. 
28/10/2020 
n/a 
B.II.d.1.h - Change in the specification parameters 
and/or limits of the finished product - Update of the 
dossier to comply with the provisions of an updated 
general monograph of the Ph. Eur. for the finished 
product 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
II/0004/G 
This was an application for a group of variations. 
17/09/2020 
n/a 
B.I.b.1.f - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0002 
B.II.g.2 - Introduction of a post approval change 
17/09/2020 
n/a 
management protocol related to the finished product 
IB/0001 
B.II.g.5.c - Implementation of changes foreseen in 
02/09/2020 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
Page 14/14 
 
 
 
 
 
 
 
 
 
 
 
 
